HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

Key Points

• HC Wainwright lowered Viridian Therapeutics’ Q3 2026 EPS estimate to a loss of $1.13 per share from $1.09, while forecasting continued losses through 2029 before projecting a $0.40 profit in 2030.
• Viridian reported a Q2 loss of $1.05 per share, missing the $1.03 consensus estimate, despite revenue of $0.28 million exceeding the $0.06 million forecast.
• Analyst sentiment remains broadly positive, with 13 Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $38.93 versus the stock’s $23.59 opening price.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will earn ($1.13) per share for the quarter, down from their prior estimate of ($1.09). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q4 2026 earnings at ($1.21) EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($2.87) EPS, FY2029 earnings at ($1.49) EPS and FY2030 earnings at $0.40 EPS.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Weiss Ratings downgraded Viridian Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Wall Street Zen lowered Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Royal Bank Of Canada lifted their target price on Viridian Therapeutics from $35.00 to $36.00 and gave the company an "outperform" rating in a research report on Friday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $38.93.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $23.59 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The business has a 50-day simple moving average of $18.38 and a 200 day simple moving average of $21.59. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -7.00 and a beta of 0.91.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%.

Institutional Investors Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. MetLife Investment Management LLC grew its holdings in shares of Viridian Therapeutics by 0.8% during the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company's stock worth $1,369,000 after purchasing an additional 356 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Viridian Therapeutics by 0.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company's stock valued at $4,337,000 after purchasing an additional 380 shares in the last quarter. US Bancorp DE raised its stake in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company's stock valued at $53,000 after purchasing an additional 463 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Viridian Therapeutics by 0.3% during the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company's stock valued at $4,235,000 after purchasing an additional 659 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock valued at $669,000 after purchasing an additional 876 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source